Immutep Ltd.

04/08/2021 | Press release | Distributed by Public on 04/07/2021 16:20

Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metastatic Head & Neck Cancer